Text Size:AAA

LGALS3 Protein, Antibody, ELISA Kit, cDNA Clone

Description: Active
Expression host: E. coli
  • Slide 1
10289-HNAE-E-10
10289-HNAE-E-20
10 µg / $178
20 µg / $298
Add to Cart

LGALS3 Related Areas

LGALS3 Related Pathways

LGALS3 Related Product

    LGALS3 Summary & Protein Information

    LGALS3 Background

    Gene Summary: Galectin-3 is expressed in various tissues and organs, but is significantly absent in normal hepatocytes. However, evaluation of patient liver biopsies for galectin-3 expression revealed that hepatocellular carcinoma (HCC) frequently expressed significant levels of this lectin; 76% were immunohistochemically positive. Further investigations showed that galectin-3 expression in HCC is independent of whether the patient had prior hepatitis B virus infection (Hsu et al., 1999). Hsu et al. (1999) suggested that deregulated expression of galectin-3 can result in tumor transformation and invasiveness, or confer propensity for tumor cell survival.
    General information above from NCBI
    Subunit structure: Probably forms homo- or heterodimers. Interacts with DMBT1 (By similarity). Forms a complex with the ITGA3, ITGB1 and CSPG4. Interacts with LGALS3BP, LYPD3, CYHR1 and UACA.
    Subcellular location: Cytoplasm. Nucleus. Secreted. Note=Secreted by a non-classical secretory pathway and associates with the cell surface.
    Tissue specificity: A major expression is found in the colonic epithelium. It is also abundant in the activated macrophages.
    Involvement in disease: Hypomagnesemia 2 (HOMG2) [MIM:154020]: A disorder due to primary renal wasting of magnesium. Plasma levels of other electrolytes are normal. The only abnormality found, in addition to low magnesium levels, is lowered renal excretion of calcium resulting in hypocalciuria. Note=The disease is caused by mutations affecting the gene represented in this entry.
    Sequence similarity: Contains 1 galectin domain.
    General information above from UniProt

    LGALS3 Alternative Name

    LGALS3 Related Studies

  • Dumic J, et al. (2006) Galectin-3: an open-ended story. Biochim Biophys Acta. 1760(4): 616-35.
  • Sharma UC, et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 110(19): 3121-8.
  • Yan YP, et al. (2009) Galectin-3 mediates post-ischemic tissue remodeling. Brain Res. 1288: 116-24.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"